Protein Polymer Technologies Requests FDA Approval to Initiate Human Clinical
Trials
SAN DIEGO, Dec. 31 -- Protein Polymer Technologies,
Inc. (Nasdaq PPTI), announced that the Company has requested authorization
from the U.S. Food and Drug Administration to begin human clinical testing
of its urethral bulking agent for treatment of female stress urinary incontinence.
Pending FDA approval of the Company's application (formally termed an "Investigational
Device Exemption" or IDE), the Company plans to initiate clinical trials
in the second quarter of 1999.
Protein Polymer Technologies, Inc., is a San Diego-based
company focused on developing products to improve medical and surgical outcomes.
In addition to its urethral bulking agent for the treatment of stress urinary
incontinence, other targeted products include dermal augmentation agents
for cosmetic, plastic and reconstructive surgery, tissue adhesives and sealants,
scaffolds for wound healing and tissue engineering, and depots for local
drug delivery.
